Background: Majority of BC express hormone receptors and cyclin dependent kinases especially CDK4/6 have been proven to mediate hormone therapy resistance. Many CDK 4/6 inhibitors have shown survival benefits. Yet, the VTE risk remains considerable. We undertook an updated meta-analysis of RCTs to determine the VTE risk among patients with hormone receptor-positive metastatic BC treated with CDK 4/6 inhibitors. Methods: MEDLINE, EMBASE databases and meeting abstracts from inception through March 2018 were queried. RCTs that mention VTE as adverse effect were incorporated in the meta-analysis. The primary meta-analytic approach was a fixed effects model using the Mantel-Haenszel (MH) method. It was used to calculate the estimated pooled risk ratio (RR) and risk difference (RD) with 95% confidence interval (CI). Results: Five phase III studies and one phase II study with a total of 3,159 patients were eligible. The study arms used palbociclib-letrozole, palbociclib-fulvestrant, ribociclibletrozole, abemaciclib-fulvestrant, abemaciclib-letrozole/anastrozole while the control arms utilized placebo in combination with letrozole or anastrozole or fulvestrant. The I 2 statistic for heterogeneity was 16.452, and the heterogeneity X 2 (Cochran's Q) was 5 (P ¼ 0.308), suggesting homogeneity among RCTs. The VTE incidence was 40 (2.03%) in CDK 4/6 inhibitors group vs 5 (0.42%) in control group. The pooled RR for VTE in CDK 4/6 inhibitors group was 3.561 (95% CI: 1. 574 to 8.057, P ¼ 0.002) and the absolute RD was 0.014 (95% CI: 0.002 to 0.027, P ¼ 0.022) according to the fixed effects model. By the random effects model, the pooled RR was 3.072 (95% CI: 1.138 to 8.294, P ¼ 0.027) and RD was 0.015 (95% CI: 0.007 to 0.023, P < 0.0001). Conclusions: Our meta-analysis showed that the addition of CDK 4/6 inhibitors to letrozole or fulvestrant, contribute to higher incidence of VTE. Patients on CDK 4/6 inhibitors group experienced a significant increase in the VTE risk with a RR of 3.56. VTE remains the second leading cause of death in cancer patients receiving antineoplastic therapy and close monitoring is required. Background: No data are available on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated BC pts. Methods: A 26-item survey exploring fertility preservation and pregnancy after BC was emailed to physicians attending the 2016 3 rd ESO-ESMO BCY3 and the 2017 15 th St. Gallen BCC 2017 conferences. The present analysis investigated potential differences in physicians' knowledge, attitudes and practice towards these issues in BC pts with or without BRCA mutations. The McNemar test for paired proportions was used for statistical comparison. Results: The survey was completed by 273 physicians (105 at BCY3 and 168 at BCC 2017) with a median age of 46 years (range 38-55); the majority were medical oncologists (56%) practicing in an academic setting (86%). A comparable proportion of respondents suggested the use of either embryo (43% vs. 39%; p ¼ 0.11) or oocyte (62% vs. 63%; p ¼ 0.77) cryopreservation as available options for BC pts with or without BRCA mutations, respectively. Conversely, ovarian tissue cryopreservation (33% vs. 40%; p ¼ 0.009) and GnRHa during chemotherapy (74% vs. 81%; p ¼ 0.001) were less commonly suggested in BRCA-mutated BC pts than in BC pts without BRCA mutations. 42% agreed or were neutral on the statement that controlled ovarian stimulation should not be considered safe in BRCA-mutated BC pts. 45% and 30% agreed or
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